Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Galapagos NV (GLPG)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
27.02 -0.36    -1.31%
05:13:40 - Real-time Data. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Netherlands
ISIN:  BE0003818359 
  • Volume: 14,542
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 26.86 - 27.10
Galapagos 27.02 -0.36 -1.31%

Galapagos NV Company Profile

 
Get an in-depth profile of Galapagos NV, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

1338

Equity Type

ORD

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Contact Information

Address Generaal De Wittelaan L11 A3
Mechelen, 2800
Belgium
Phone 32 1 534 29 00
Fax 32 1 534 29 01

Top Executives

Name Age Since Title
Paulus A. Stoffels 61 2022 CEO, Chairman, Interim Head of R&D
Jerome Contamine 66 2022 Lead Independent Non-Executive Director
Elisabeth Svanberg 62 2020 Independent Non-Executive Director
Peter Guenter 61 2019 Independent Non-Executive Director
Simon J. Sturge 65 2023 Independent Non-Executive Director
Andrew D. Dickinson 54 2024 Non-Executive Non-Independent Director
Linda Slanec Higgins 62 2019 Non-Executive Non-Independent Director
Susanne Schaffert 57 2023 Non-Executive Independent Director
Daniel G. Baker 74 2022 Non-Executive Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GLPG Comments

Write your thoughts about Galapagos NV
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Eren Eren
Eren Eren Jan 27, 2022 4:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
75 eoy
Hold This Sheet
Hold This Sheet Aug 20, 2021 7:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$45 soon
Hold This Sheet
Hold This Sheet Aug 20, 2021 7:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Here we are…
Meet Bryan
Meet Bryan Jun 24, 2021 6:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
UPDATE 2!! DO NOT BUY THIS YET!!! I Just found out where the bottom for this stock is = 43 to 47 EURO for this year! If the bottom is reached next year it will be a bit higher. Trust me.
Show previous replies (3)
Meet Bryan
Meet Bryan Jun 24, 2021 6:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
true, but the technicals are almost at a PERFECT buy
Mr Buffett
Mr Buffett Jun 24, 2021 6:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Meet Bryan Forget about technical analysis for this stock at this stage. The big fall from 253 was due to fundamental setback, i.e. most important medicine (Filgotinib) not approved by FDA and no interesting new medicine candidates to be expected on the short term.
Meet Bryan
Meet Bryan Jun 24, 2021 6:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mr Buffett, you're clueless.
Mr Buffett
Mr Buffett Jun 24, 2021 6:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Fine. Good luck with your crystal ball.
Eren Eren
Eren Eren Jun 24, 2021 6:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
You were soo right!!! And what will happen now? Is it bottommed finally and where is the top technically speaking.
Meet Bryan
Meet Bryan May 27, 2021 10:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Update: it looks like it broke out of the falling wedge. The odds of this going higher are better now
Deepak QTP
Deepak QTP May 27, 2021 10:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Lol u turd minded. Keep talking bull and then bear anf then bull thesis🤣
Jan Hendrickx
Jan Hendrickx May 07, 2021 8:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
nice job on profit! now a beautiful takeover. I'm guessing Pharming Group
Ludo Huibers
Ludo Huibers May 06, 2021 3:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
no earnings today? or they failed even on that???
Hold This Sheet
Hold This Sheet Apr 28, 2021 5:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
45$ is a good entry point
Meet Bryan
Meet Bryan Feb 23, 2021 1:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
161410494356645.jpg
This trash is going to 32 Euro. Have fun!
Jan Hendrickx
Jan Hendrickx Feb 23, 2021 1:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ooh, u bougt in too high?
Meet Bryan
Meet Bryan Feb 23, 2021 1:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
RF RF
RF RF Feb 22, 2021 6:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Ready for takeover?!
RF RF
RF RF Feb 22, 2021 6:43PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It makes for a good takeover now!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email